ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

5.150 +0.260 (+5.32%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	87,514
Open	4.890
Bid (Size)	5.000 (200)
Ask (Size)	5.380 (100)
Prev. Close	4.890
Today's Range	4.770 - 5.320
52wk Range	3.920 - 19.14
Shares Outstanding	101,102,152
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

Today 15:36 EDT

From Pomerantz LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Today 10:00 EDT

From Schall Law

Via GlobeNewswire

Performance

YTD	-71.0%	-71.0%
1 Month	-12.3%	-12.3%
3 Month	-12.4%	-12.4%
6 Month	-65.8%	-65.8%
1 Year	-12.0%	-12.0%

More News

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

April 10, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 10, 2026

From Schall Law

Via GlobeNewswire

ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

April 07, 2026

From Kirby McInerney LLP

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

April 07, 2026

From Pomerantz LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 07, 2026

From Schall Law

Via GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

April 06, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ATRA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Atara Biotherapeutics, Inc. Investors - Contact Kirby McInerney LLP by May 22, 2026

April 03, 2026

From Kirby McInerney LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 03, 2026

From Schall Law

Via GlobeNewswire

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

April 02, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Deadline Approaching: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

April 01, 2026

From Law Offices of Howard G. Smith

Via Business Wire

ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

April 01, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

March 31, 2026

From Pomerantz LLP

Via GlobeNewswire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 31, 2026

From Schall Law

Via GlobeNewswire

Law Offices of Frank R. Cruz Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

March 31, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

March 30, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

March 28, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

March 27, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) and Encourages Investors to Contact the Firm

March 27, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

March 26, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 26, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATRA

March 26, 2026

From DJS Law Group

Via Business Wire

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 25, 2026

From The Schall Law Firm

Via Business Wire

Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

March 25, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Frequently Asked Questions

Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?

Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.

What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?

Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?

The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market

What is the current price of Atara Biotherapeutics, Inc. - Common Stock?

The current price of Atara Biotherapeutics, Inc. - Common Stock is 5.150

When was Atara Biotherapeutics, Inc. - Common Stock last traded?

The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 04/14/26 04:00 PM ET

What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?

The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 520.68M

How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?

Atara Biotherapeutics, Inc. - Common Stock has 521M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.